Acarbose is again on the stage  

作　　者：Mustafa Altay 

机构地区：[1]Department of Endocrinology and Metabolism,University of Health Sciences Turkey,Keçiören Health Administration and Research Center,Keçiören 06290,Ankara,Turkey

出　　处：《World Journal of Diabetes》2022年第1期1-4,共4页世界糖尿病杂志（英文版）（电子版）

摘　　要：Acarbose is an agent that has been used to treat type 2 diabetes for about 30 years;it prevents postprandial hyperglycemia by inhibiting carbohydrate digestion in the small intestine.Since incretin-based treatments have been preferred over the last 10 to 15 years,the use of acarbose is not as common in treating type 2 diabetes as before.Some studies have shown that acarbose also produces a weight-loss effect by increasing glucagon-like peptide 1(GLP-1).The positive effect of acarbose on GLP-1,and increasing evidence that it provides cardiovascular protection,suggests that acarbose may again be considered among the first-choice antidiabetic agents,as it was in the 1990s.

关 键 词：ACARBOSE Cardiovascular protection Glucagon-like peptide 1 OBESITY Waist-to-height ratio 

分 类 号：R977.15[医药卫生—药品]